Patents Assigned to EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITY
-
Patent number: 12221418Abstract: Disclosed is a montelukast berberine double salt or composition with anti-inflammatory, antibacterial and immunomodulatory effects. Particularly, disclosed are a montelukast berberine quaternary ammonium salt with a structure as represented by formula (I), a double salt or a composition, a solvate, a hydrate, an isotope substitution or an isomer thereof.Type: GrantFiled: November 16, 2022Date of Patent: February 11, 2025Assignee: EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITYInventor: Wei Chen
-
Patent number: 12220411Abstract: Application of a PTGDS inhibitor in preparation of a drug for treating cataracts is provided. As an effective and selective PTGDS inhibitor, AT-56 competitively inhibits production of PGD2 by occupying a catalytic site of PTGDS. The PTGDS catalyzes synthesis of the PGD2 to cause an oxidative stress injury of human lens epithelial cells, thereby promoting occurrence and development of aging and opacity of a lens. By reducing apoptosis caused by the oxidative stress injury, a degree of the cataracts can be effectively reduced.Type: GrantFiled: October 8, 2023Date of Patent: February 11, 2025Assignee: THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITYInventors: Jin Li, Jiasheng Liu, Yitong Xu, Mengchao Zhu, Haisen Sun
-
Publication number: 20250041211Abstract: The present invention discloses an ophthalmic preparation and an application thereof in the treatment of presbyopia. The ophthalmic preparation includes aceclidine and rebamipide. It is found and proved in the present invention for the first time that the aceclidine and the rebamipide are combined to produce a synergistic effect, the rebamipide can enhance an effect of the aceclidine and reduce related side effects, and the aceclidine can effectively produce a synergistic effect with the rebamipide to contract the pupillary sphincter and have a dosage effect. The ophthalmic preparation can effectively improve, alleviate or treat presbyopia, have a potential effect of slowing down the progression of the presbyopia course, and have a very good clinical application prospect.Type: ApplicationFiled: October 22, 2024Publication date: February 6, 2025Applicant: EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITYInventor: Wei Chen
-
Publication number: 20250037794Abstract: The present invention belongs to the technical fields of biomedicine and gene detection, and particularly relates to a group of SNP markers related to myopia or high myopia and use thereof. Specifically, the SNP sites include an SNP site combination related to myopia or high myopia, comprising: one or more of rs10484690, rs117984746, rs1196455, rs143477571, rs143580489, rs189212243, rs2296651, rs2303221, rs2547319, rs26173, rs3817585, rs41303763, rs42688, rs61746299, rs78587889, and rs80094829.Type: ApplicationFiled: October 13, 2024Publication date: January 30, 2025Applicants: EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITY, CENTER OF OPTOMETRY INTERNATIONAL INNOVATION OF WENZHOUInventors: Liangde Xu, Hong Wang, Jia Qu
-
Publication number: 20240165089Abstract: The present application relates to a method for treating myopia with vipocetine, which can effectively prevent myopia and/or control the progression of myopia while being safe and free of obvious side effects, having good prospects for clinical application.Type: ApplicationFiled: January 19, 2024Publication date: May 23, 2024Applicant: EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITYInventors: Xiangtian Zhou, Sen Zhang, Jia Qu, Qinyuan Zheng
-
Patent number: 11419761Abstract: A glaucoma aqueous humor drainage device and a glaucoma aqueous humor drainage method, wherein the opening and closing of a pressure valve is controlled by the change in the pressure in a cavity of the valve. When the pressure in the intraocular pressure exceeds 12 mmHg, the valve is opened, and a drainage tube connected behind the valve drains the aqueous humor to the ocular surface, reducing the patient's discomfort and dry eyes, effectively draining the aqueous humor and avoiding scarring caused by embedding the device via a conjunctival flap and operation failure caused by increase of intraocular pressure caused by generation of filtering blebs.Type: GrantFiled: July 22, 2020Date of Patent: August 23, 2022Assignee: THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITYInventors: Yuanbo Liang, Chengtan Liu, Liang Wen, Yanqian Xie
-
Patent number: 10959412Abstract: A method for creating an animal model of traumatic optic nerve injury, including fully exposing an internal segment of an optic canal as well as adjacent anterior skull base, posterior ethmoid sinus and lateral sphenoid sinus walls through an ethmoid sinus-sphenoid sinus operation pathway under an endoscope, and impacting different sites of the internal segment of the optic canal with controllable impact force to cause optic nerve injury so as to prepare a controllable and quantifiable TONI bionic elastic injury animal model reflecting contusion to an internal segment of an optic canal in a human TONI clinical injury state. With less intracranial combined injury to the animal, the survival rate is high. Different sites of the optic canal are impacted with quantifiable elastic force for the quantitative and qualitative purposes with respect to the injured parts and the injury degree.Type: GrantFiled: July 24, 2017Date of Patent: March 30, 2021Assignee: The Eye Hospital of Wenzhou Medical UniversityInventors: Wencan Wu, Kaihui Nan, Ende Wu, Yuanyuan Chen, Jing Zhou
-
Patent number: 10932900Abstract: A method of sutureless intrascleral haptic-hook lens implantation which improves the fixation process of the lens haptics, allowing the lens haptics to be bent and folded back into the vitreous cavity to generate a better stability, avoiding the complication of intrascleral fixation haptic slippage, meanwhile forming a sclera lamellar groove between two adjacent scleral incisions to bury the lens haptics. The method may be adapted to patients in need of intraocular lens implantation without sufficient capsular support, such as aphakia, intraocular lens, lens dislocation, etc. This method enhances the stability and centrality of the lens, the surgical procedures are simple and easy to master, which reduces the operation time.Type: GrantFiled: April 26, 2019Date of Patent: March 2, 2021Assignee: THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITYInventor: Ronghan Wu